Zenas Biopharma, INC Form 4 insider transactions

Joseph L. Farmer, President and Chief Operating Officer of Zenas BioPharma, Inc., was granted 175,000 stock options with an exercise price of $11.94, vesting over four years.

A recent SEC Form 4 filing reveals that Tomas Kiselak, a director of Zenas BioPharma, Inc. and Managing Member of Fairmount Funds Management LLC, was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Zenas BioPharma, Inc. Director Patrick G. Enright was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Zenas BioPharma, Inc. Director John J. Orloff was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

A director at Zenas BioPharma, Inc. has acquired 18,500 stock options, indicating potential confidence in the company's future performance.

Zenas BioPharma's Chief Executive Officer and Director, Leon O. Moulder Jr., was granted 400,000 stock options with an exercise price of $11.94, vesting over a four-year period.

Xiao Ting, a director at Zenas BioPharma, files an amended SEC Form 4/A to correct the number of shares beneficially owned following a recent transaction.

Lisa von Moltke, Head of Research and Development and Chief Medical Officer at Zenas BioPharma, acquired stock options for 400,000 shares on April 15, 2025.

Zenas BioPharma's CEO, Leon O. Moulder Jr., recently purchased 25,000 shares of common stock at an average price of $6.67 per share.

Director Xiao Ting of Zenas BioPharma, Inc. purchased 10,000 shares of common stock at a weighted average price of $7.76 on February 7, 2025.

Jennifer A. Fox, Chief Business Officer and Chief Financial Officer of Zenas BioPharma, acquired 8,125 stock options on December 16, 2024.

Orlando Oliveira, Chief Commercial Officer of Zenas BioPharma, Inc., was granted stock options on December 16, 2024.

Zenas BioPharma's CEO, Leon O. Moulder Jr., has increased his holdings in the company through open market purchases of common stock.

Zenas BioPharma's CEO, Leon O. Moulder Jr., has increased his holdings in the company through recent open market purchases of common stock.

Zenas BioPharma's CEO, Leon O. Moulder Jr., has been actively purchasing company stock, increasing his indirect holdings.

Wellington Biomedical Innovation Master Investors converted Series A, B, and C Convertible Preferred Stock into common stock of Zenas BioPharma upon the closing of the company's initial public offering on September 16, 2024.

Enavate Sciences GP, LLC and Zebra Aggregator, LP report changes in beneficial ownership of Zenas BioPharma, Inc. common stock following the conversion of preferred stock in connection with the company's initial public offering.

Fairmount Funds Management LLC files an amended Form 4 to correct previously reported amounts of securities beneficially owned following Zenas BioPharma's IPO and the conversion of preferred stock to common stock.

Leon O. Moulder, Jr., CEO of Zenas BioPharma, files an amended Form 4 detailing the conversion of preferred stock to common stock and a new stock option grant following the company's initial public offering.

Director Hongbo Lu reports the acquisition of 58,823 shares of Zenas BioPharma through an indirect holding.

Director John J Orloff reports the acquisition of stock options in Zenas BioPharma, Inc.

Director Xiao Ting acquired 37,000 stock options in Zenas BioPharma, Inc. on September 12, 2024, according to a Form 4 filing.

Director Hongbo Lu reports acquiring 37,000 stock options in Zenas BioPharma, Inc.

Patricia L. Allen, a director of Zenas BioPharma, acquired stock options for 18,500 shares on September 12, 2024.

Director Patrick G. Enright reports the conversion of Series B and C Convertible Preferred Stock into common stock and the acquisition of stock options following Zenas BioPharma's IPO.

Director James P. Boylan of Zenas BioPharma, Inc. received stock options for 37,000 shares at an exercise price of $17 on September 12, 2024.

Director Jason Nunn reports changes in beneficial ownership of Zenas BioPharma stock following the company's initial public offering, including the conversion of preferred stock and stock option grants.

Fairmount Funds Management and related parties report the conversion of preferred stock to common stock and an option grant following Zenas BioPharma's initial public offering.

Orlando Oliveira, Chief Commercial Officer of Zenas BioPharma, acquired stock options for 410,000 shares of common stock on September 12, 2024.

SR One Capital Management and Simeon George report changes in beneficial ownership of Zenas BioPharma common stock following the conversion of preferred stock in connection with the company's initial public offering.